Establishing a National Egyptian HLH Re… | Clinical Trial

Key information

Conditions

HLH Hemic and Lymphatic Diseases Hemophagocytic Lymphohistiocytoses Histiocytosis Histiocytosis, Non-Langerhans-Cell Lymphatic Diseases Lymphohistiocytosis, Hemophagocytic

Age range

Up to 18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Faculty of Medicine Pediatric Hematology Oncology Department, Cairo, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients diagnosed with hlh

Exclusion criteria

adults

Treatment and study plan

Primary outcomes

A nationwide HLH map

Time frame: 2 years

Establish a nationwide map for children with presumed diagnosis of HLH

Study contacts

Contact information is provided by the study sponsor or research team.

Fatma Ebeid Professor of pediatrics, Ain Shams University, Professor

CONTACT

+201095569596

Iman Ragab Prof of Pediatrics, Ain Shams University, Professor

CONTACT

[email protected]

+20 1002550680

Sponsors and collaborators

Lead sponsor

Ain Shams University

Other

Registry information

Acronym: NEHR

Important dates

Study start: 2024
Primary completion: 2028
Study completion: 2028
First posted: Sep 2, 2026
Registry last updated: Sep 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting